Abstract:Antimicrobial resistance is a global threat that if left unchecked could lead to 10 million annual mortalities by 2050. One factor contributing to the rise of multi-drug-resistant (MDR) pathogens is the reliance on traditional culture-based pathogen identification (ID) and antimicrobial susceptibility testing (AST) that typically takes several days. This delay of objective pathogen ID and AST information to inform clinical decision making results in clinicians treating patients empirically often using first-line, broad-spectrum antibiotics, contributing to the misuse/overuse of antibiotics. To combat the rise in MDR pathogens, there is a critical demand for rapid ID and AST technologies. Among the advances in ID and AST technologies in the past decade, single-cell diagnostic technologies powered by droplet microfluidics offer great promise due to their potential for high-sensitivity detection and rapid turnaround time. Our laboratory has been at the forefront of developing such technologies and applying them to diagnosing urinary tract infections (UTIs), one of the most common infections and a frequent reason for the prescription of antimicrobials. For pathogen ID, we first demonstrated the highly sensitive, amplification-free detection of single bacterial cells by confining them in picoliter-scale droplets and detection with fluorogenic peptide nucleic acid (PNA) probes that target their 16S rRNA (rRNA), a well-characterized marker for phylogenic classification. We subsequently improved the PNA probe design and enhanced detection sensitivity. For single-cell AST, we first employed a growth indicator dye and engineered an integrated device that allows us to detect growth from single bacterial cells under antibiotic exposure within 1 h, equivalent to two to three bacterial replications. To expand beyond testing a single antibiotic condition per device, a common limitation for droplet microfluidics, we developed an integrated programmable droplet microfluidic device for scalable single-cell AST. Using the scalable single-cell AST platform, we demonstrated the generation of up to 32 droplet groups in a single device with custom antibiotic titers and the capacity to scale up single-cell AST, and providing reliable pathogen categories beyond a binary call embodies a critical advance. Finally, we developed an integrated ID and AST platform. To this end, we developed a PNA probe panel that can identify nearly 90% of uropathogens and showed the quantitative detection of 16S rRNA from single bacterial cells in droplet-enabled AST after as little as 10 min of antibiotic exposure. This platform achieved both ID and AST from minimally processed urine samples in 30 min, representing one of the fastest turnaround times to date. In addition to tracing the development of our technologies, we compare them with contemporary research advances and offer our perspectives for future development, with the vision that single-cell ID and AST technologies powered by droplet microfluidics can indeed become a useful diagnostic tool for combating antimicrobial resistance.

Artificial intelligence‐assisted point‐of‐care testing system for ultrafast and quantitative detection of drug‐resistant bacteria

Artificial Intelligence-Driven Quantification of Antibiotic-Resistant Bacteria in Food by Color-Encoded Multiplex Hydrogel Digital LAMP

Biosensor for Β-Lactam Antibiotics Residue Detection-A Review

Rapid and visual identification of β-lactamase subtypes for precision antibiotic therapy

An Integrated Microfluidic Chip-Mass Spectrometry System for Rapid Antimicrobial Resistance Analysis of Bacteria Producing Β-Lactamases

Hardware-Free Testing for Antimicrobial Resistance Using Artificial Intelligence

AI-based mobile application to fight antibiotic resistance

Rapid personalized AMR diagnostics using two-dimensional antibiotic resistance profiling strategy employing a thermometric NDM-1 biosensor

Biosensors and Point‐of‐Care Devices for Bacterial Detection: Rapid Diagnostics Informing Antibiotic Therapy

Detection of ESKAPE Bacterial Pathogens at the Point of Care Using Isothermal DNA-Based Assays in a Portable Degas-Actuated Microfluidic Diagnostic Assay Platform

A novel machine-learning aided platform for rapid detection of urine ESBLs and carbapenemases: URECA-LAMP

A Dual-Channel Electrochemical Biosensor Enables Concurrent Detection of Pathogens and Antibiotic Resistance

Rapid bacterial detection and antibiotic susceptibility testing in whole blood using one-step, high throughput blood digital PCR

Nanoplasmonic Rapid Antimicrobial‐Resistance Point‐of‐Care Identification Device: RAPIDx

Microfluidic Filter Device Coupled Mass Spectrometry for Rapid Bacterial Antimicrobial Resistance Analysis.

Rapid Antimicrobial Susceptibility Testing on Clinical Urine Samples by Video-Based Object Scattering Intensity Detection

Rapid, direct, visualized and antibody-free bacterial detection with extra species identification and susceptibility evaluation capabilities

Combating Antimicrobial Resistance via Single-Cell Diagnostic Technologies Powered by Droplet Microfluidics

Rapid Detection of Bacterial Resistance to β-Lactam Antibiotics with a Relay-Response Chemiluminescence Assay

A Multiplex Fluidic Chip for Rapid Phenotypic Antibiotic Susceptibility Testing

Culture-Free Detection of β-Lactamase-Producing Bacteria in Urinary Tract Infections Using a Paper Sensor